Market Overview

Nivalis Throttled After Failed Drug Trial, Multiple Downgrades

Related NVLS
15 Biggest Mid-Day Losers For Wednesday
22 Stocks Moving In Wednesday's Pre-Market Session

Nivalis Therapeutics Inc (NASDAQ: NVLS) shares are trading lower by $3.60 (57 percent) at $2.65 in Tuesday's session.

After the close on Monday, the company reported it failed to demonstrate benefit in absolute change in predicted FEV1 or in Sweat Chloride Reduction at 12 weeks.

The failed trial has prompted four Wall Street firms to downgrade the issue including Raymond James, Cowen, Baird and Stifel.

After a lower open, it managed a slight bounce to $3.04 before continuing its move lower. It has continued to make new lows for the day, with the current standing at $2.58. That far exceeds its former all-time low that was made in March at $3.68.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (NVLS)

View Comments and Join the Discussion!

Partner Center